Aug 18, 2025 02:08PM Jefferies Reiterates Hold Rating on Mineralys Therapeutics, Inc. (MLYS)

Aug 12, 2025 04:09PM Mineralys Therapeutics, Inc. (MLYS) Tops Q2 EPS by 40c

Jul 14, 2025 08:20AM Jefferies Reiterates Hold Rating on Mineralys Therapeutics, Inc. (MLYS)

Jun 30, 2025 11:19AM Mineralys Therapeutics (MLYS) announces positive results from Phase 3 Launch-HTN trial

Jun 18, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)

Jun 17, 2025 07:00AM Mineralys Therapeutics (MLYS) Announces Positive Topline Results from Phase 2 Explore-CKD Trial

Jun 10, 2025 04:15PM Jefferies Starts Mineralys Therapeutics, Inc. (MLYS) at Hold

May 20, 2025 08:01AM Mineralys Therapeutics (MLYS) Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection

May 12, 2025 04:28PM Mineralys Therapeutics, Inc. (MLYS) Tops Q1 EPS by 29c

Apr 23, 2025 05:25PM Mineralys Therapeutics (MLYS) announces publication of phase 2 Advance-HTN results

Mar 31, 2025 08:18AM Stifel Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)

Mar 17, 2025 08:00AM Mineralys Therapeutics (MLYS) Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat

Mar 11, 2025 10:20PM Mineralys Therapeutics (MLYS) Announces Pricing of $175.0 Million Underwritten Public Offering

Mar 10, 2025 04:03PM Goldman Sachs Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)

Mar 10, 2025 04:01PM Mineralys Therapeutics (MLYS) Announces Proposed $250M Share Offering

Mar 10, 2025 10:40AM Stifel Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)

Mar 10, 2025 07:01AM Mineralys Therapeutics (MLYS) Announces Positive Topline Results from Launch-HTN and Advance-HTN Trials of Lorundrostat

Mar 7, 2025 04:01PM Mineralys Therapeutics (MLYS) to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

Feb 25, 2025 09:40AM Stifel Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)

Feb 12, 2025 07:04AM Mineralys Therapeutics, Inc. (MLYS) Misses Q4 EPS by 27c

Feb 4, 2025 08:06AM Mineralys Therapeutics (MLYS) Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria

Jan 8, 2025 08:06AM Mineralys Therapeutics (MLYS) Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension

Nov 11, 2024 04:06PM Mineralys Therapeutics, Inc. (MLYS) Misses Q3 EPS by 42c

Aug 14, 2024 05:52AM Goldman Sachs Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)

Aug 14, 2024 05:23AM Stifel Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)

Aug 13, 2024 04:07PM Mineralys Therapeutics, Inc. (MLYS) Misses Q2 EPS by 11c

Jul 10, 2024 06:18AM H.C. Wainwright Starts Mineralys Therapeutics, Inc. (MLYS) at Buy

Jun 14, 2024 08:01AM Mineralys Therapeutics (MLYS) Appoints Alexander M. Gold to its Board